Physician profile
John J Mazzucco
NPI 1275515322
$1,320.42
in general payments reported to CMS, 2019-2025
13 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2021: $64.18 · 2022: $182 · 2023: $532 · 2024: $260 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $946.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $421.79 | 2023-2025 | Signia, Endo Gia Ultra, Eea |
| Myriad Genetic Laboratories, INC. | $342.00 | 2021-2024 | Myrisk |
| Inari Medical, INC. | $141.72 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Medtronic Vascular, INC. | $127.22 | 2019 | |
| Lemaitre Vascular, INC. | $117.69 | 2022 | |
| Innocoll Pharmaceuticals Limited | $31.73 | 2022 | |
| Ethicon US, LLC | $31.14 | 2021 | |
| Solventum Corporation | $24.65 | 2025 | V.A.C.Ulta, Prevena, V.A.C. Veraflo Cleanse Choice |
| Becton, Dickinson and Company | $19.04 | 2024 | Phasix Mesh |
| Baxter Healthcare | $18.12 | 2024 | Tisseel |
| Kerecis Limited | $15.83 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Pacira Pharmaceuticals Incorporated | $15.82 | 2023 | Exparel, Iovera |
| Hologic Sales and Service, LLC | $13.67 | 2023 | Biozorb |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mazzucco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.